Skip to main content
Premium Trial:

Request an Annual Quote

CardioDx Raises $58M in Private Financing

NEW YORK (GenomeWeb News) – Cardiovascular genomics diagnostics company CardioDx today announced the completion of a $58 million equity financing round.

The company, which recently received Medicare coverage for its coronary artery disease test called Corus CAD, will use the funding to support commercialization of the gene expression test and to develop other genomics diagnostics for cardiovascular disease, it said.

David Levison, president and CEO of CardioDx, said in a statement that the cash injection positions the company to capitalize on the "significant" opportunity to improve the lives of patients with obstructive coronary artery disease, and the Medicare decision "further validates the clinical benefit of and economic rationale for Corus CAD. This additional capital will help us expand our sales force in the US, further broaden reimbursement coverage, and support continued investments in research and development of new products."

Corus CAD was launched in June 2009 as a laboratory-developed test.

Investors in the financing round include Singapore-based investment firm Temasek, as well as existing investors Longitude Capital; Artiman Ventures; Kleiner, Perkins, Caufield & Byers; JP Morgan; Mohr Davidow Ventures; TPG Biotech; Intel Capital; Acadia Woods Partners; Bright Capital; Pappas Ventures; DAG Ventures; Asset Management Group; and GE Capital.

All previous investors also participated in the round, CardioDx said.

In May 2011, the Palo Alto, Calif.-based company raised $60 million in private financing.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.